Neurotrophic factors for the treatment of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 13, Issue SUPPL. 3, 2007, Pages

  Chiocco, Matthew J ^a   Harvey, Brandon K ^a   Wang, Yun ^a   Hoffer, Barry J ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

BDNF; BMP7; Bone morphogenetic protein 7; Brain derived neurotrophic factor; GDNF; Glial cell line derived neurotrophic factor; Neurodegenerative disease; Neurotrophic factor; Neurturin; NTN; Parkinson's disease

Indexed keywords

ADENOVIRUS VECTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLECYSTOKININ; CONSERVED DOPAMINE NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; LEVODOPA; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; NEURTURIN; OSTEOGENIC PROTEIN 1; RASAGILINE; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; MOLECULE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGENERATION;

ANIMALS; DOPAMINE; HUMANS; NERVE DEGENERATION; NERVE GROWTH FACTORS; NEURONS; PARKINSON DISEASE;

EID: 38949135182     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(08)70024-5     Document Type: Article

References (108)

1. Sariola H., and Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 116 (2003) 3855-3862
2. Beck K., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R., et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 (1995) 339-341
3. Hoffer B., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., et al. Glial cell line-derived neurotrophic factor reverses toxin- induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182 (1994) 107-111
4. Kearns C., Cass W., Smoot K., Kryscio R., and Gash D. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 17 (1997) 7111-7118
5. Sullivan A., Opacka-Juffry J., and Blunt S. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line- derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 10 (1998) 57-63
6. Tomac A., Lindqvist E., Lin L., Ogren S., Young D., Hoffer B., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
7. Martin D., Miller G., Cullen T., Fischer N., Dix D., and Russell D. Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats. Eur J Pharmacol 317 (1996) 247-256
8. Martin D., Miller G., Fischer N., Diz D., Cullen T., and Russell D. Glial cell line-derived neurotrophic factor: the lateral cerebral ventricle as a site of administration for stimulation of the substantia nigra dopamine system in rats. Eur J Neurosci 8 (1996) 1249-1255
9. Bowenkamp K., Lapchak P., Hoffer B., Miller P., and Bickford P. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Exp Neurol 145 (1997) 104-117
10. Kirik D., Rosenblad C., and Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 12 (2000) 3871-3882
11. Aoi M., Date I., Tomita S., and Ohmoto T. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system. Neurol Res. 22 (2000) 832-836
12. Aoi M., Date I., Tomita S., and Ohmoto T. GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration. Acta Neurochir 142 (2000) 805-810
13. Gash D., Zhang Z., Ovadia A., Cass W., Yi A., Simmerman L., et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 (1996) 252-255
14. Miyoshi Y., Zhang Z., Ovadia A., Lapchak P., Collins F., Hilt D., et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 42 (1997) 208-214
15. Zhang Z., Miyoshi Y., Lapchak P., Collins F., Hilt D., Lebel C., et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 282 (1997) 1396-1401
16. Gerhardt G., Cass W., Huettl P., Brock S., Zhang Z., and Gash D. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 817 (1999) 163-171
17. Costa S., Iravani M., Pearce R., and Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur J Pharmacol 412 (2001) 45-50
18. Grondin R., Zhang Z., Yi A., Cass W., Maswood N., Andersen A., et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125 (2002) 2191-2201
19. Kordower J., Palfi S., Chen E., Ma S., Sendera T., Cochran E., et al. Clinicopathological findings following intraventricular glial- derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46 (1999) 419-424
20. Nutt J., Burchiel K., Comella C., Jankovic J., Lang A., Laws Jr. E., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2003) 69-73
21. Gill S., Patel N., Hotton G., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 (2003) 589-595
22. Patel N., Bunnage M., Plaha P., Svendsen C., Heywood P., and Gill S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57 (2005) 298-302
23. Slevin J., Gerhardt G., Smith C., Gash D., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102 (2005) 216-222
24. Lang A., Langston J., Stoessl A., Brodsky M., Brooks D., Dhawan V., et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 5 (2006) 200-202
25. Slevin J., Gash D., Smith C., Gerhardt G., Kryscio R., Chebrolu H., et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106 (2007) 614-620
26. Lindner M., Winn S., Baetge E., Hammang J., Gentile F., Doherty E., et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 132 (1995) 62-76
27. Date I., Shingo T., Yoshida H., Fujiwara K., Kobayashi K., Takeuchi A., et al. Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant 10 (2001) 397-401
28. Shingo T., Date I., Yoshida H., and Ohmoto T. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF- producing cells in a rat model of Parkinson's disease. J Neurosci Res 69 (2002) 946-954
29. Yasuhara T., Shingo T., Muraoka K., Kobayashi K., Takeuchi A., Yano A., et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg 102 (2005) 80-89
30. Duan D., Yang H., Zhang J., Zhang J., and Xu Q. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease. Exp Brain Res 161 (2005) 316-324
31. Ericson C., Georgievska B., and Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci 22 (2005) 2755-2764
32. Ericson C., Wictorin K., and Lundberg C. Ex vivo and in vitro studies of transgene expression in rat astrocytes transduced with lentiviral vectors. Exp Neurol 173 (2002) 22-30
33. Akerud P., Canals J., Snyder E., and Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 21 (2001) 8108-8118
34. Behrstock S., Ebert A., McHugh J., Vosberg S., Moore J., Schneider B., et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther 13 (2006) 379-388
35. Yasuhara T., Matsukawa N., Hara K., Yu G., Xu L., Maki M., et al. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J Neurosci 26 (2006) 12497-12511
36. Chiang Y., Borlongan C., Zhou F., Hoffer B., and Wang Y. Transplantation of fetal kidney cells: neuroprotection and neuroregeneration. Cell Transplant 14 (2005) 1-9
37. Park K., Eglitis M., and Mouradian M. Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res 40 (2001) 315-323
38. Espejo E., Gonzalez-Albo M., Moraes J., El Banoua F., Flores J., and Caraballo I. Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra- adrenal chromaffin cells of the Zuckerkandl's organ. J Neurosci 21 (2001) 9888-9895
39. Korecka J., Verhaagen J., and Hol E. Cell-replacement and gene- therapy strategies for Parkinson's and Alzheimer's disease. Regen Med 2 (2007) 425-446
40. Linazasoro G. Cell therapy for Parkinson's disease: only young onset patients allowed?. Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease. Cell Transplant 15 (2006) 463-473
41. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J., Mallet J., et al. Intrastriatal injection of an adenoviral vector expressing glial- cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 94 (1997) 8818-8823
42. Choi-Lundberg D., Lin Q., Chang Y., Chiang Y., Hay C., Mohajeri H., et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 (1997) 838-841
43. Kojima H., Abiru Y., Sakajiri K., Watabe K., Ohishi N., Takamori M., et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem Biophys Res Com. 238 (1997) 569-573
44. Lapchak P., Araujo D., Hilt D., Sheng J., and Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 777 (1997) 153-160
45. Mandel R., Spratt S., Snyder R., and Leff S. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line- derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 94 (1997) 14083-14088
46. Kirik D., Rosenblad C., Bjorklund A., and Mandel R. Long-term rAAV- mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20 (2000) 4686-4700
47. McGrath J., Lintz E., Hoffer B., Gerhardt G., Quintero E., and Granholm A. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplant 11 (2002) 215-227
48. Wang L., Muramatsu S., Lu Y., Ikeguchi K., Fujimoto K., Okada T., et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9 (2002) 381-389
49. Monville C., Torres E., Thomas E., Scarpini C., Muhith J., Lewis J., et al. HSV vector-delivery of GDNF in a rat model of PD: partial efficacy obscured by vector toxicity. Brain Res 1024 (2004) 1-15
50. Bensadoun J., Deglon N., Tseng J., Ridet J., Zurn A., and Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 164 (2000) 15-24
51. Kordower J., Emborg M., Bloch J., Ma S., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
52. Palfi S., Leventhal L., Chu Y., Ma S., Emborg M., Bakay R., et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22 (2002) 4942-4954
53. Georgievska B., Kirik D., Rosenblad C., Lundberg C., and Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13 (2002) 75-82
54. Dowd E., Monville C., Torres E., Wong L., Azzouz M., Mazarakis N., et al. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci 22 (2005) 2587-2595
55. Svendsen C. The first steps towards gene therapy for Parkinson's disease. Lancet Neurol 6 (2007) 754-756
56. Kotzbauer P., Lampe P., Heuckeroth R., Golden J., Creedon D., Johnson Jr. E., et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 (1996) 467-470
57. Creedon D., Tansey M., Baloh R., Osborne P., Lampe P., Fahrner T., et al. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc Natl Acad Sci USA 94 (1997) 7018-7023
58. Horger B., Nishimura M., Armanini M., Wang L., Poulsen K., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18 (1998) 4929-4937
59. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11 (1999) 1554-1566
60. Akerud P., Alberch J., Eketjall S., Wagner J., and Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem 73 (1999) 70-78
61. Oiwa Y., Yoshimura R., Nakai K., and Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 947 (2002) 271-283
62. Liu W., Lu G., Li B., and Chen S. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease. Parkinsonism Relat Disord 13 (2007) 77-88
63. Ye M., Wang X., Zhang Y., Lu G., Liang L., Xu J., et al. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Brain Res 1142 (2007) 206-216
64. Fjord-Larsen L., Johansen J., Kusk P., Tornoe J., Gronborg M., Rosenblad C., et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 195 (2005) 49-60
65. Gasmi M., Herzog C., Brandon E., Cunningham J., Ramirez G., Ketchum E., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 15 (2007) 62-68
66. Kordower J., Herzog C., Dass B., Bakay R., Stansell III J., Gasmi M., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60 (2006) 706-715
67. Herzog C., Dass B., Holden J., Stansell III J., Gasmi M., Tuszynski M., et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22 (2007) 1124-1132
68. Gasmi M., Brandon E., Herzog C., Wilson A., Bishop K., Hofer E., et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE- 120 for Parkinson's disease. Neurobiol Dis 27 (2007) 67-76
69. Check E. Second chance. Nat Med 13 (2007) 770-771
70. Lein P., Johnson M., Guo X., Rueger D., and Higgins D. Osteogenic protein-1 induces dendritic growth in rat sympathetic neurons. Neuron 15 (1995) 597-605
71. Nonner D., Barrett E., Kaplan P., and Barrett J. Bone morphogenetic proteins (BMP6 and BMP7) enhance the protective effect of neurotrophins on cultured septal cholinergic neurons during hypoglycemia. J Neurochem 77 (2001) 691-699
72. Lein P., Beck H., Chandrasekaran V., Gallagher P., Chen H., Lin Y., et al. Glia induce dendritic growth in cultured sympathetic neurons by modulating the balance between bone morphogenetic proteins (BMPs) and BMP antagonists. J Neurosci 22 (2002) 10377-10387
73. Tsai M., Weng C., Shyue S., Liou D., Chen C., Chiu C., et al. Dual effect of adenovirus-mediated transfer of BMP7 in mixed neuron-glial cultures: Neuroprotection and cellular differentiation. J Neurosci Res 85 (2007) 2950-2959
74. Jordan J., Bottner M., Schluesener H., Unsicker K., and Krieglstein K. Bone morphogenetic proteins: neurotrophic roles for midbrain dopaminergic neurons and implications of astroglial cells. Eur J Neurosci 9 (1997) 1699-1709
75. Chen H., Lein P., Wang J., Gash D., Hoffer B., and Chiang Y. Expression of bone morphogenetic proteins in the brain during normal aging and in 6-hydroxydopamine-lesioned animals. Brain Res 994 (2003) 81-90
76. Soderstrom S., Bengtsson H., and Ebendal T. Expression of serine/threonine kinase receptors including the bone morphogenetic factor type II receptor in the developing and adult rat brain. Cell Tissue Res 286 (1996) 269-279
77. Harvey B., Mark A., Chou J., Chen G., Hoffer B., and Wang Y. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease. Brain Res 1022 (2004) 88-95
78. Cook S. Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. Orthopedics 22 (1999) 669-671
79. Friedlaender G., Perry C., Cole J., Cook S., Cierny G., Muschler G., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A Suppl 1 (2001) S151-S158
80. Vaccaro A., Anderson D., Patel T., Fischgrund J., Truumees E., Herkowitz H., et al. Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine 30 (2005) 2709-2716
81. Bilic R., Simic P., Jelic M., Stern-Padovan R., Dodig D., van Meerdervoort H., et al. Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis. Int Orthop 30 (2006) 128-134
82. Kanayama M., Hashimoto T., Shigenobu K., Yamane S., Bauer T., and Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine 31 (2006) 1067-1074
83. Buijs J., Henriquez N., van Overveld P., van der Horst G., Que I., Schwaninger R., et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67 (2007) 8742-8751
84. Ristiniemi J., Flinkkila T., Hyvonen P., Lakovaara M., Pakarinen H., and Jalovaara P. RhBMP-7 accelerates the healing in distal tibial fractures treated by external fixation. J Bone Joint Surg 89 (2007) 265-272
85. Giannoudis P., and Tzioupis C. Clinical applications of BMP-7: the UK perspective. Injury 36 Suppl 3 (2005) S47-S50
86. Leibrock J., Lottspeich F., Hohn A., Hofer M., Hengerer B., Masiakowski P., et al. Molecular cloning and expression of brain- derived neurotrophic factor. Nature 341 (1989) 149-152
87. Liu Q., Walther D., Drgon T., Polesskaya O., Lesnick T., Strain K., et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet 134 (2005) 93-103
88. Chen H., and Weber A. BDNF enhances retinal ganglion cell survival in cats with optic nerve damage. Invest Ophthalmol Vis Sci 42 (2001) 966-974
89. Coull J., Beggs S., Boudreau D., Boivin D., Tsuda M., Inoue K., et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438 (2005) 1017-1021
90. Li Y., Jia Y., Cui K., Li N., Zheng Z., Wang Y., et al. Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. Nature 434 (2005) 894-898
91. Lykissas M., Batistatou A., Charalabopoulos K., and Beris A. The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res 4 (2007) 143-151
92. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J., and Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411 (2001) 86-89
93. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270 (1999) 45-48
94. Parain K., Murer M., Yan Q., Faucheux B., Agid Y., Hirsch E., et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10 (1999) 557-561
95. Zhang X., Andren P., and Svenningsson P. Repeated L-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res 1095 (2006) 207-210
96. Yoshimoto Y., Lin Q., Collier T., Frim D., Breakefield X., and Bohn M. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res 691 (1995) 25-36
97. Levivier M., Przedborski S., Bencsics C., and Kang U. Intrastriatal implantation of fibroblasts genetically engineered to produce brain- derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 15 (1995) 7810-7820
98. Frim D., Uhler T., Galpern W., Beal M., Breakefield X., and Isacson O. Implanted fibroblasts genetically engineered to produce brain- derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 91 (1994) 5104-5108
99. Galpern W., Frim D., Tatter S., Altar C., Beal M., and Isacson O. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant 5 (1996) 225-232
100. Klein R., Lewis M., Muzyczka N., and Meyer E. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res 847 (1999) 314-320
101. Sun M., Kong L., Wang X., Lu X., Gao Q., and Geller A. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 1052 (2005) 119-129
102. Lapchak P., Araujo D., and Hefti F. BDNF and trkB mRNA expression in the rat hippocampus following entorhinal cortex lesions. Neuroreport 4 (1993) 191-194
103. Chun H., Son J., and Son J. Identification of potential compounds promoting BDNF production in nigral dopaminergic neurons: clinical implication in Parkinson's disease. Neuroreport 11 (2000) 511-514
104. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., and Youdim M. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18 (2004) 1471-1473
105. Sagi Y., Mandel S., Amit T., and Youdim M. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25 (2007) 35-44
106. Petrova P., Raibekas A., Pevsner J., Vigo N., Anafi M., Moore M., et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20 (2003) 173-188
107. Zhou C., Xiao C., Commissiong J., Krnjevic K., and Ye J. Mesencephalic astrocyte-derived neurotrophic factor enhances nigral gamma-aminobutyric acid release. Neuroreport 17 (2006) 293-297
108. Lindholm P., Voutilainen M., Lauren J., Peranen J., Leppanen V., Andressoo J., et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448 (2007) 73-77